# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Soquelitinib is a potential first-in-class ITK inhibitor with broad potential in cancer and immune diseases There are currently...
Corvus Pharma (NASDAQ:CRVS) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.12)...
Oppenheimer analyst Jeff Jones maintains Corvus Pharma (NASDAQ:CRVS) with a Outperform and raises the price target from $7 t...
Corvus Pharma (NASDAQ:CRVS) reported quarterly losses of $(0.12) per share which met the analyst consensus estimate.
Corvus Pharmaceuticals, Inc. (Corvus or the Company) (NASDAQ:CRVS) (GLOBAL NEWSWIRE), a clinical-stage biopharmaceutical compan...